Echinocandins–structure, mechanism of action and use in antifungal therapy

M Szymański, S Chmielewska… - Journal of Enzyme …, 2022‏ - Taylor & Francis
With increasing number of immunocompromised patients as well as drug resistance in fungi,
the risk of fatal fungal infections in humans increases as well. The action of echinocandins is …

Oral candidiasis: A disease of opportunity

T Vila, AS Sultan, D Montelongo-Jauregui… - Journal of fungi, 2020‏ - mdpi.com
Oral candidiasis, commonly referred to as “thrush,” is an opportunistic fungal infection that
commonly affects the oral mucosa. The main causative agent, Candida albicans, is a highly …

Invasive candidiasis

PG Pappas, MS Lionakis, MC Arendrup… - Nature Reviews …, 2018‏ - nature.com
Invasive candidiasis is an important health-care-associated fungal infection that can be
caused by several Candida spp.; the most common species is Candida albicans, but the …

The global problem of antifungal resistance: prevalence, mechanisms, and management

DS Perlin, R Rautemaa-Richardson… - The Lancet infectious …, 2017‏ - thelancet.com
All serious fungal infections need appropriate antifungal therapy for successful patient
outcome. Only a few classes of antifungal drugs are available, so the emergence of …

Drug-resistant fungi: an emerging challenge threatening our limited antifungal armamentarium

A Arastehfar, T Gabaldón, R Garcia-Rubio, JD Jenks… - Antibiotics, 2020‏ - mdpi.com
The high clinical mortality and economic burden posed by invasive fungal infections (IFIs),
along with significant agricultural crop loss caused by various fungal species, has resulted in …

Antifungal resistance: current trends and future strategies to combat

NP Wiederhold - Infection and drug resistance, 2017‏ - Taylor & Francis
Antifungal resistance represents a major clinical challenge to clinicians responsible for
treating invasive fungal infections due to the limited arsenal of systemically available …

Invasive candidiasis

BJ Kullberg, MC Arendrup - New England Journal of Medicine, 2015‏ - Mass Medical Soc
Despite advances in antifungal therapy, the mortality associated with invasive candidiasis
remains as high as 40%. This review summarizes recent trends and current strategies …

Molecular evolution of antifungal drug resistance

N Robbins, T Caplan, LE Cowen - Annual review of …, 2017‏ - annualreviews.org
The fungal pathogens Candida albicans, Cryptococcus neoformans, and Aspergillus
fumigatus have transitioned from a rare curiosity to a leading cause of human mortality. The …

Emerging threats in antifungal-resistant fungal pathogens

D Sanglard - Frontiers in medicine, 2016‏ - frontiersin.org
The use of antifungal drugs in the therapy of fungal diseases can lead to the development of
antifungal resistance. Resistance has been described for virtually all antifungal agents in …

Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections

KJ Shaw, AS Ibrahim - Journal of Fungi, 2020‏ - mdpi.com
Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment
of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix …